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Introduction: An excessive response to ovarian hyperstimulation during IVF is associated with 54 
patient discomfort and complications. This individual patient data (IPD) meta-analysis,  evaluates 55 
whether ovarian reserve tests (ORTs) add prognostic value to patient characteristics, like female age in 56 
the identification of excessive responders, and whether their performance differs across clinical 57 
subgroups. 58 
Methods: We searched for studies published until December 2009 of basal FSH, AMH or AFC in 59 
relation to ovarian response to ovarian hyperstimulation and authors were invited to share their 60 
original data. Random intercept logistic regression models were used to estimate the added value of 61 
the ORTs on patient characteristics, while accounting for between study heterogeneity. ROC 62 
regression analyses were performed to study the effect of specific patient characteristics on the 63 
accuracy of the ORTs.  64 
Results: Thirty-two databases could be included (n=5,251). Age had an area under the ROC curve 65 
(AUC) of 0.61 for excessive response prediction. AFC and AMH significantly added prognostic value 66 
to age (P-value for each <0.001). A model with age, AFC and AMH had an AUC of 0.85. The 67 
combination AMH and AFC, without age had similar accuracy (P=0.98). The subgroup analysis 68 
showed that FSH performed worse (P=0.01) in predicting excessive response in higher age groups, 69 
AFC did better (P=0.01) and AMH performed about the same (p=0.14).  70 
Conclusion: This IPD meta-analysis demonstrates that AFC and AMH add value to female age in the 71 
prediction of excessive response and that, for some ORTs, the discriminatory performance is affected 72 
by female age. ORTs, and specifically AMH, may thus be useful for excessive response prediction in 73 
IVF-populations.   74 
Introduction 75 
In women undergoing in vitro fertilization (IVF), the development of a large number of oocytes 76 
complicates up to thirty percent of IVF cycles (Delvigne and Rozenberg, 2002).  Such an excessive 77 
response may lead to poorer quality embryos, lower chances of pregnancy, or cycle cancellation 78 
(Baart, Martini et al., 2006;Heijnen, Eijkemans et al., 2007) (Verberg, Eijkemans et al., 2009) (van der 79 
Gaast, Eijkemans et al., 2006). Additionally, patients with an excessive response are at risk of 80 
developing ovarian hyperstimulation syndrome (OHSS), a potentially life threatening condition 81 
(Fauser, Diedrich et al., 2008) . To maximize safety and efficacy of assisted reproductive technology 82 
(ART) programs, there is a need to identify patients at risk of an excessive response at the start of 83 
IVF/ICSI treatment, and to apply effective measures to prevent such an excessive response from 84 
occurring.   85 
Several patient characteristics such as a lean habitus, young age and the presence of polycystic 86 
ovary syndrome (PCOS) have been identified as conditions that predispose patients to OHSS (Ho, Lee 87 
et al., 2003). Unfortunately, precise expressions of the predictive accuracy of these characteristics are 88 
not available. In contrast, ovarian reserve tests (ORTs), such as Anti-Müllerian Hormone (AMH), 89 
Antral Follicle Count (AFC) and Follicle Stimulation Hormone (FSH) have been assessed for their 90 
value in the prediction of an excessive response (Broer, Mol et al., 2010) (van Rooij, Broekmans et 91 
al., 2002a) (Eldar-Geva, Ben Chetrit et al., 2005b) (Nakhuda, Chu et al., 2006) (Riggs, Duran et al., 92 
2008) (Nardo, Gelbaya et al., 2009). It is not clear, however, what ORTs add to predictive and readily 93 
available patient characteristics, such as age.  94 
As ovarian reserve decreases with age, it is conceivable that the predictive value of the ORTs 95 
also depends on female age. Alternatively, the accuracy of the antral follicle count may be more 96 
complicated in women with a higher BMI. Moreover, BMI could further influence the predictive 97 
accuracy by possibly reducing the biologic availability of recombinant FSH for ovarian stimulation, 98 
and thereby creating spuriously reduced ovarian responses (Steinkampf, Hammond et al., 2003). Most 99 
predictive accuracy studies, however, had a limited sample size, lacking the power to evaluate patient 100 
characteristics as modifiers of accuracy in specific subgroups and the ability to analyze the added 101 
value of the ORTs on patient characteristics. 102 
To overcome the problem of small studies with restricted power, the current study applied an 103 
individual patient database (IPD) meta-analysis approach. By aggregating data on the level of the 104 
individual patient, more precise estimates of accuracy, evaluations of added accuracy, and 105 
identification of accuracy modifiers becomes possible while taking between study heterogeneity into 106 
account appropriately.  107 
 108 
Material and Methods 109 
Data acquisition 110 
We searched for existing literature for studies on the value of FSH, AFC and AMH in predicting IVF 111 
outcome. We expanded searches from conventional systematic reviews on the subject and another IPD 112 
meta-analysis (IPD-IMPORT) on poor response prediction; searches were updated to include studies 113 
up to the end of 2009. (Broekmans, Kwee et al., 2006) (Broer, Mol et al., 2009) (Broer, Eijkemans et 114 
al., 2011) (Broer, 2011) (Broer, Mol et al., 2010).   115 
Keywords used in the systematic Medline search included synonyms for In Vitro Fertilization 116 
(IVF, controlled ovarian stimulation, in vitro fertilisation) and synonyms for the various tests (FSH, 117 
Follicle Stimulating Hormone, AFC, Antral Follicle Count or number, AMH, Anti-Müllerian 118 
Hormone, Müllerian inhibiting substance). Studies presenting data on ovarian response to 119 
hyperstimulation, at least one ovarian reserve test (ORT) and at least one patient characteristic were 120 
eligible for the current review. All titles and abstracts were evaluated for eligibility by two authors 121 
(MD and SB or SB and JvD). If necessary the opinion of a third author was decisive (FB). 122 
All authors of potentially eligible primary studies were informed about this individual patient 123 
data (IPD) meta-analysis initiative and invited to share their data in a collaborative project. If authors 124 
were inclined to participate, they were provided with a data request form, informing them on the 125 
format of the data requested  126 
  After data acquisition, all data were scrutinized on quality and consistency and, whenever 127 
possible, converted into a single format. Any issues or inconsistencies were checked with the original 128 
author. For a more detailed description of the IPD meta-analysis methodology the reader is referred to 129 
previous papers (Broeze, Opmeer et al., 2009;Broeze, Opmeer et al., 2011). 130 
Within all eligible studies, a comparison was made between those studies that could and those 131 
that could not be included. Sensitivity and specificity pairs for excessive response prediction were 132 
calculated for the ORTs under study, using the thresholds for excessive response that had been set in 133 
each study. Spearman correlations were then calculated for sensitivity and specificity pairs across 134 
studies, to ascertain that the differences in sensitivity and specificity levels between included and not 135 
included studies were likely the result of different threshold levels used, thereby reducing the 136 
likelihood of bias in the final analysis.  137 
We evaluated the quality of the included studies using the QUADAS checklist, supplemented 138 
by a number of items to evaluate the risk of bias in prognostic studies. Whenever a particular variable 139 
was missing in an individual database or in an individual case within a database, data were not 140 
imputed. Baseline characteristics were analyzed in the total IPD dataset and for each of the individual 141 
studies.  142 
Definitions 143 
An excessive response was defined as the retrieval of more than 15 oocytes. This cut-off was selected 144 
as the definition for excessive responsive in most primary studies varied between more than 14 and 145 
more than 16 oocytes (Broer, Dolleman et al., 2011). Duration of subfertility was defined as the period 146 
from cessation of oral contraceptives and/or start of unprotected intercourse until the first IVF attempt. 147 
In the included studies, patients had been stimulated according to local protocol, resulting in a wide 148 
range of FSH dosages. In almost all studies a starting dosage of at least 150 International Units (IU) 149 
was given. This dosage is considered the optimal daily dosage in expected normal responders; with 150 
this dose it may be assumed that all patients received adequate stimulation, creating growth of all 151 
follicles sensitive to FSH within the time frame of exposure (Sterrenburg, Veltman-Verhulst et al., 152 
2011) 153 
Predictive accuracy was defined as the ability of the model to distinguish excessive responders 154 
from cases with a normal or poor response. We calculated Areas Under the Receiver–Operator 155 
Characteristic Curve (ROC-AUC) for the ORTs in the prediction of excessive response for each 156 
individual study and for the pooled studies were calculated as a summary statistic of predictive 157 
accuracy.  158 
 159 
 160 
Statistical Analysis 161 
Analyses were done in two steps. First, the added value of ORTs on top of the patient characteristics 162 
age, BMI and duration of subfertility was assessed. As a part of this analysis, we assessed whether 163 
these results may have been influenced by differences in study characteristics or FSH dosage 164 
administered. Secondly, we examined whether the predictive performance depends on the patient 165 
characteristics age, BMI, and duration of subfertility.  166 
 167 
Prediction of an excessive response using ORTs and patient characteristics 168 
To study whether ORTs have an added value on top of patient characteristics in the prediction of an 169 
excessive response we used random intercept logistic regression models. The random intercept model 170 
takes heterogeneity into account by assuming that included studies are a random sample of a potential 171 
universe of studies, and that between-study variation in the incidence of excessive response in this 172 
universe can be described by a normal distribution on the log odds scale. These models were created to 173 
quantitatively estimate the added value that ORTs have on patient characteristics in predicting an 174 
excessive response. It provides both an estimate of the summary predictive effect as well as of the 175 
variance of this distribution.  176 
Three different sets of models were used for the prediction of excessive response. The first set 177 
of models included the patient characteristics female age, BMI, and duration of subfertility. In the 178 
second set of models, the predictive capacity of each of the individual ovarian reserve tests (FSH, AFC 179 
and AMH) was estimated. In the third set of multivariate models, the added value of combinations of 180 
ovarian reserve tests on top of patient characteristics was evaluated.  181 
 The next step was to construct receiver operating characteristic (ROC) curves to express the 182 
predictive accuracy of each combination of predictive variables in distinguishing excessive responders 183 
from the rest. With each of the random intercept logistic regression models, we calculated the 184 
probability of an excessive response. By moving the positivity threshold from 0 to 1, we could then 185 
calculate sensitivity-specificity pairs for each model. Based on these, we plotted stratified ROC curves 186 
with the ROC regression model as proposed by Janes and Pepe (Janes, Longton et al., 2009;Pepe, 187 
Longton et al., 2009). This model assumes that studies share a common ROC for each ORT, but 188 
allows the positivity threshold corresponding to each sensitivity-specificity pair to vary between 189 
studies. With this model the improvement in predictive accuracy of adding an ORT to other variables 190 
can be studied, while correcting for the heterogeneity between studies. This way we could compare the 191 
ROC and AUCs of the models described above and evaluate the statistical significance of any 192 
differences.  193 
Because not all studies in this meta-analysis had included data for all three ORTs, we 194 
constructed prediction models using those databases from the total dataset that included the 195 
corresponding ovarian reserve tests (FSH, AFC and AMH) and age to allow for a direct comparison. 196 
The results of all analyses in the three-test study subgroup were verified in the total study group. 197 
To account for between study differences in FSH dosage protocols and their potential effect on 198 
excessive response, we repeated the analyses as described above while adding starting FSH dosage as 199 
a covariate. In a similar fashion, we included study design features, as identified by the QUADAS 200 
checklist, as covariates in our models, in order to evaluate whether differences in FSH dosage or study 201 
design influenced the observed associations between ORT, patient characteristics and the outcome 202 
excessive response (Whiting, Rutjes et al., 2011). 203 
 204 
Influence of age, BMI and duration of subfertility on the accuracy of ORTs in excessive response 205 
prediction 206 
To study whether the accuracy of  ORTs in the prediction of excessive response is modified by patient 207 
age, BMI or duration of subfertility we used the ROC regression model proposed by Pepe and Janes 208 
(Janes, Longton et al., 2009;Pepe, Longton et al., 2009). This model allows us to study the effects of 209 
patient or disease characteristics on the classification accuracy of tests. In this model, the ORT ROC 210 
curves are modeled as a function of the covariates age, BMI and duration of subfertility.  211 
We assumed the effect of the covariate in this meta-analysis to be identical across studies, but, 212 
as in the previous analysis, the positivity threshold corresponding to each sensitivity-specificity pair 213 
was allowed to vary between studies, thereby correcting for any heterogeneity between studies. The 214 
areas under the corresponding ROC curves (AUC) were calculated in order to express the 215 
discriminatory capacity (accuracy) of the ORT in women in the respective subgroups.  216 
Data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, Il, USA) and R version 2.9.0. 217 
(http://www.r-project.org/). Random intercept logistic regression prediction models were created with 218 
the ‘Lme4’ library, using the Laplace approximation to the likelihood. 219 
 220 
Results 221 
Data acquisition 222 
A total of 32 databases, used for the preparation of 57 or more manuscripts, could be included in this 223 
IPD-study. Twenty-seven had been previously included in the IPD-IMPORT study (Broer, 2011). Ten 224 
additional studies were identified from the systematic MEDLINE search. We invited these authors and 225 
asked them for permission to use their databases in the present analysis on excessive response 226 
prediction. Only four of these authors sent their data (Aflatoonian, Oskouian et al., 2009) (Freour, 227 
Mirallie et al., 2007) (Gnoth, Schuring et al., 2008) (Nardo, Gelbaya et al., 2009); one of them 228 
submitted two separate databases (Nardo, Gelbaya et al., 2009). In total 32 datasets could be included 229 
in the EXPORT study project database, with data from 5,251 study participants (Figure 1).  230 
With the original data we were able to replicate the primary findings of the original study in 13 231 
databases. In 12 cases, the study database we received contained a number of patients that differed 232 
from the publication, whereas in 7 other databases there were slight inconsistencies with the baseline 233 
data as previously published. These inconsistencies were discussed with the corresponding author and 234 
could be resolved in most cases. Through this process, the level of consistency between the individual 235 
data and the data reported in the published manuscripts was regarded sufficient for all included 236 
studies.  237 
 238 
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 246 
For the comparison of the included and not included studies, we attempted to calculate 247 
sensitivity and specificity of the ORTs in the prediction of excessive response. However, of the non-248 
included studies only one reported sensitivity and specificity values for AFC in the prediction of an 249 
excessive response. Therefore, Spearman correlation could not be calculated. Nonetheless, for the 250 
majority of the studies this was performed in the IMPORT study (Broer, 2011), a related IPD study 251 
from the same research group focused on poor response prediction. In that study it was demonstrated 252 
that there was no difference in the correlations between sensitivity and specificity for included and 253 
non-included studies on poor response. Since there was no difference in poor response prediction, it is 254 
reasonable to assume that there is also no difference for excessive response prediction. We therefore 255 
assumed that no obvious bias has occurred for the present analysis by excluding studies based on the 256 
EXPORT studies 
Aflatoonian et al., 2009 ; (Ashrafi, Madani et al., 2005;Yong, Baird et al., 2003;Bancsi, Huijs et 
al., 2000;Caroppo, Matteo et al., 2006;Luna, Grunfeld et al., 2007;Eldar-Geva, Ben Chetrit et 
al., 2005a;Erdem, Erdem et al., 2004;Liu and Greenblatt, 2008;Jayaprakasan, Hilwah et al., 
2007;Klinkert, Broekmans et al., 2005;Kwee, Elting et al., 2003;La Marca, Giulini et al., 
2007;McIlveen, Skull et al., 2007;Merce, Barco et al., 2007;Ng, Tang et al., 2000;Ng, Chan et 
al., 2005;Muttukrishna, Suharjono et al., 2004;Muttukrishna, McGarrigle et al., 2005;Nelson, 
Yates et al., 2007;Popovic-Todorovic, Loft et al., 2003a;Popovic-Todorovic, Loft et al., 
2003c;Smeenk, Stolwijk et al., 2000;Smeenk, Sweep et al., 2007;Tomas-C, Nuojua-Huttunen- 
et al., 1997;van Swieten, Leeuw-Harmsen et al., 2005;van Rooij, Broekmans et al., 
         
 
availability of primary data. Baseline characteristics of the original studies are summarized in Table A-257 
1 of the online supplementary data. 258 
 259 
Data from 4,786 out of the 5,251 women were suitable for the analysis of prediction of 260 
excessive response, of which 894 (19%) had an excessive response. The other women were not 261 
suitable as the primary outcome was ongoing pregnancy and not oocyte yield. Baseline characteristics 262 
of the total study group are summarized in Table 1.  263 
 264 
Statistical analyses 265 
Prediction of an excessive response using ORTs and patient characteristics 266 
For the model building exercises, we could use data of 1,023 women for excessive response analysis. 267 
This was the number of women for whom all five variables of interest were known: age, AFC, AMH, 268 
FSH and the number of oocytes retrieved after stimulation. Of the evaluated patient characteristics, 269 
age was the strongest single predictor of excessive response (OR 0.89; 95% CI: 0.85 to 0.93). BMI 270 
and duration of subfertility were not significantly predictive of excessive response (Addendum Table 271 
A-IV).  272 
We compared the ORTs using the random intercept logistic regression model in predicting 273 
excessive response (see Table 2). The ROC regression analysis showed a high accuracy for AMH 274 
(AUC 0.81: 95% CI 0.76 to0.87) and for AFC (AUC 0.79: 95% CI 0.74 to 0.84), but only a moderate 275 
accuracy for FSH (AUC 0.66: 95% CI 0.60 to 0.73) (Table 3). 276 
The multivariable analyses demonstrated that a model including age, AFC and AMH (AUC 277 
0.85) had a significantly higher predictive accuracy than a model based on age alone (AUC 0.61; 278 
p=<0.001). Addition of FSH to this model did not further improve predictive accuracy (AUC 0.85; p = 279 
0.73) (Table 3). Interestingly, a single AMH or AFC test had a comparable accuracy (AUC 0.81 and 280 
0.79, respectively). Addition of AMH to AFC and of AFC to AMH significantly improved accuracy (p 281 
= <0.001 or p=0.003, respectively). A model combining these two tests resulted in an AUC of 0.85. 282 
Age did not add value to this model (p = 0.98). The ROC curves corresponding to the multivariable 283 
models are shown in Figure 2.  284 
 285 
Effect of FSH dosage and study protocol on excessive response outcome 286 
Patients had been stimulated with a wide range of FSH dosages according to their center’s local 287 
protocol. The mean FSH dosage was 204.28 IU (IQR=150-225 IU). Women who developed an 288 
excessive response tended to have received a lower starting dosage of FSH than women who did not 289 
develop an excessive response.  The mean dosage was 201.75 IU in those women who developed an 290 
excessive response versus a mean dosage of 224.79 IU for women who did not have an excessive 291 
response (p-value for difference <0.001). FSH dosage had a significant, negative association with 292 
excessive response development. A higher FSH dosage was associated with a lower chance of an 293 
excessive response in both the three-test study group and in the group as a whole (OR 0.99: p<0.001). 294 
When FSH dosage was included in the multivariable model as an additional covariate (in addition to 295 
age and the ORTs) the odds-ratios for age and the ORTs, adjusted for FSH dosage, remained basically 296 
unchanged. 297 
Study quality characteristics as scored by QUADAS checklist and supplemental questions are 298 
shown in Figure 2.  Overall, data were of high quality, with the exception of verification bias. This 299 
implies that the test results may have been known to the clinician taking decisions on patient 300 
management. Additional study characteristics with regard to sampling, data collection and study 301 
design are shown in Table A-I, addendum. None of the study characteristics that were assessed were 302 
associated with excessive response development (p-value range 0.34-0.89). Similarly, the odds-ratios 303 
for age and the ORTs, adjusted for study characteristics, remained basically unchanged.  304 
 305 
Influence of age, BMI and duration of subfertility on the accuracy of ORTs in excessive response 306 
prediction 307 
The results of the ROC regression model which studied the effect of several patient characteristics on 308 
the ROC curve of the ORTs in the prediction of an excessive response are shown in Table 4. The 309 
accuracy of FSH was significantly lower in women with a higher age (p = 0.01).  310 
For a 20 year old the AUC for FSH was 0.66. In contrast, the AUC for a 30 year old was 0.59 and 0.52 311 
for a 40 year old. The accuracy of AFC was significantly higher in women with a higher age (p = 312 
0.01).  For a 20 year old woman the AUC for AFC was 0.64, for a 30 year old it was 0.71 and for a 40 313 
year old it was 0.81. The discriminatory capacity of AMH in response prediction was not significantly 314 
influenced by age. BMI and duration of subfertility categories had no significant effect on the ROC 315 
curves, for any of the ORTs. 316 
 317 
Discussion 318 
The results of the present IPD meta-analysis, with data from 32 individual studies, demonstrate that 319 
both AFC and AMH clearly add value to female age alone in the prediction of excessive response. 320 
AMH and AFC in concert have high predictive accuracy, even without adding female age. The results 321 
also indicate that the performance of the ORTs may vary across patient subgroups, as determined by 322 
female age especially. At a higher female age FSH performs less well, while AFC performs better in 323 
younger age groups. As FSH performs the least well in excessive response prediction this finding is 324 
not very relevant. For AFC the change in predictive accuracy with increasing age is more  notable and 325 
results in  an increased predictive accuracy, in terms of an increase in the area under the curve, of 326 
approximately 0.26. However, this increase is only seen with big increments of female age (from 20 to 327 
30 years or 30 to 40 years), with smaller increases in female age such as between 31, 34 and 37 years 328 
(the 25th, 50th and 75th percentiles of age and thus the most clinically relevant group) the increase in 329 
AUC is much smaller. In addition, the gain in predictive accuracy is evenly spread over the entirety of 330 
the curve thus limiting the margin of additive clinical value. 331 
The results of this IPD meta-analysis are mostly in line with those from a previous, 332 
conventional systematic review and meta-analysis of ovarian reserve tests and excessive response 333 
(Broer, Dolleman et al., 2011) and another recent study in which AMH was able to accurately identify 334 
79% of excessive responders (Anckaert, Smitz et al., 2012). Our IPD approach allowed us to evaluate 335 
the added value of ORTs on top of female age and, moreover, allowed for the analysis of accuracy in 336 
subgroups of women defined by to age, BMI or duration of subfertility. While ORT adds value to 337 
female age in predicting excessive response, age adds little to nothing to the accuracy of the prediction 338 
based on the ORTs. It does however does seem to influence the accuracy of some ORTs. 339 
The results of this IPD meta-analysis also suggest that age influences the accuracy of AFC and 340 
basal FSH. Although ovarian reserve decreases with age, the AFC is believed to reflect the true level 341 
of the quantitative ovarian reserve directly, in contrast to basal FSH, which constitutes an indirect 342 
marker of follicle numbers. Indeed, in older women the prevalence of excessive response may become 343 
too low for any test to gain sufficient accuracy, and this may be especially true for FSH. For AFC, the 344 
change in accuracy may be significant only from the statistical point of view, without actual 345 
implications for clinical practice, and without an obvious explanatory mechanism.  346 
A challenge with the IPD approach is collecting sufficient data. For the current study 347 
databases of 60 of the eligible 125 manuscripts were obtained. We were unable to reach a number of 348 
authors, primarily because of inaccurate contact information or because authors did not reply to the e-349 
mail addresses provided. Older data were often lost or in a format that could no longer be read. Studies 350 
to investigate the possibility of combining IPD data with aggregated data are ongoing (Riley, Dodd et 351 
al., 2008). To compare included and excluded studies we aimed to calculate Spearman correlation 352 
coefficients for the included and non-included studies. Unfortunately, of the non-included studies only 353 
one reported sensitivity and specificity values for AFC in the prediction of an excessive response. 354 
Therefore, Spearman correlation could not be calculated. However, for 27 out of 32 studies a 355 
Spearman correlation was calculated from a previous IPD meta-analysis on poor response prediction 356 
and this showed that there was no difference, (Broer, Mol et al., 2010). Since there is no difference in 357 
poor response prediction, it is reasonable to assume that there is also no difference for excessive 358 
response prediction. Therefore, we believe that the current number of participants and amount of data 359 
allowed us to analyze a valid selection of all the available data. 360 
Although the current IPD meta-analysis included studies up to the end of 2009, the results of 361 
more recent studies on the value of ORTs in predicting ovarian response are still in agreement with 362 
our findings of this current IPD-meta-analysis. Two recent studies in an IVF setting (Anckaert, Smitz 363 
et al., 2012) (Andersen, Witjes et al., 2011) and three studies performed in oocyte donors or breast 364 
cancer patients undergoing oocyte cryopreservation all show an AUC of around 0.80 for AMH in 365 
excessive response prediction(Lee, Ozkavukcu et al., 2011) (Nakhuda, Douglas et al., 2011) (Riggs, 366 
Kimble et al., 2011). 367 
Using original data of a number of studies comes with between study heterogeneity. The 368 
incorporation of ovarian reserve tests and restrictions based on test results in everyday IVF practice 369 
has led to selection bias in some study populations. Heterogeneity found in the included studies 370 
pertained to differences in IVF indications, access to IVF resources, differing treatment protocols, 371 
variability in embryo laws and discordant definitions of ongoing pregnancy. There is also a variation 372 
in hormone assays and AFC sizes measured, for which no international consensus exists to correct for 373 
these differences. Consequently, no cut-off values for these tests could be used or mentioned. We have 374 
used random intercept logistic regression as well as the ROC regression model by Janes and Pepe et al. 375 
(Janes, Longton et al., 2009;Pepe, Longton et al., 2009) in which pertinent heterogeneity between 376 
studies is accounted for. 377 
The clinical value of excessive response prediction will depend on the consequences for 378 
clinical management. Several studies have looked at the effect of individualized treatment protocols. 379 
By providing women with personally tailor-made stimulation protocols, i.e. with a lower FSH dosage, 380 
it is attempted to keep the oocyte yield between 5-12 oocytes.  At present, the evidence is inconclusive 381 
upon the effectiveness of such personalized treatment regimens based on a priori prediction of ovarian 382 
response (Popovic-Todorovic, Loft et al., 2003d;Popovic-Todorovic, Loft et al., 2003b). In the study 383 
of Popovic-Todorovic the use of an individualized protocol resulted in a larger number of normal 384 
responders but a similar number of excessive responders (Popovic-Todorovic, Loft et al., 2003b). In 385 
contrast, Olivennes et al. demonstrated that lower individualized dosage protocols allow for a similar 386 
oocyte yield, implantation rate and pregnancy compared to higher dosage protocols (Olivennes, 387 
Howies et al., 2011). A third study showed no difference in the number of mature oocytes retrieved or 388 
in the occurrence of OHSS between patients that were randomly assigned to receive 225 IU or 300 IU 389 
of FSH (Jayaprakasan, Hopkisson et al., 2010). 390 
Based on the current study we cannot speculate about associations between FSH dosage and 391 
excessive response prevention. A significant association between FSH dosage and excessive response 392 
was found, with women with lower FSH dosages having higher chances of excessive response. This 393 
association probably reflects physician behavior, where lower FSH dosages are preemptively 394 
prescribed guided by specific patient characteristics, ORT results, or any comorbidity in anticipation 395 
of an excessive response. This suggests a form of selection bias, where the accuracy of ORTs or 396 
patient characteristics in the prediction of an excessive response is actually higher than currently 397 
reported, as some excessive responses may have been prevented by prescribing lower FSH dosages. 398 
The high response despite a low FSH dosage can be explained by the presence of a large number of 399 
follicles with a sensitivity for FSH close to the FSH threshold (Van der Meer, Hompes et al., 1998). 400 
More prospectively collected evidence, in the form of large scale randomized control trials is needed 401 
to demonstrate whether an individualized treatment protocol based on ORTs and patient characteristics 402 
is an truly effective strategy in the prevention of an excessive response, a protocol for such a 403 
randomized control trial was recently published (van Tilborg, Eijkemans et al., 2012). 404 
In conclusion, this IPD meta-analysis shows that AFC and AMH add predictive accuracy to 405 
age in the prediction of an excessive response. A model combining these ORTs provides good 406 
predictive accuracy, without the necessity to include female age. The performance of FSH and AFC, 407 
but not AMH, was influenced by female age but not by BMI or duration of subfertility. However, the 408 
performance across subgroups with small increments in female age seemed not to be sufficiently 409 
altered to be recognized as clinically relevant. The high predictive accuracy for both AMH and AFC or 410 
a combination of both urges the need for studies that examine the effect of ORT-based dose 411 
adaptations in which efficacy of treatment, costs and response normalization is analyzed.  412 
 413 
 414 
 415 
 416 
Acknowledgements 417 
 418 
List of contributions 419 
Data collection: A. Aflatoonian, R.A. Anderson,  M. Ashrafi,  L. Bancsi,  E. Caroppo,  A.B. 420 
Copperman,  T. Ebner,  T. Eldar-Geva,  M. Erdem,  T. Freour, C. Gnoth, E.M. Greenblatt,  K. 421 
Jayaprakasan, N. Raine-Fenning,  E. Klinkert,  J. Kwee,  A. La Marca,  C.B. Lambalk, M. McIlveen,  422 
L. Mohiyiddeen, L.T. Merce,  S. Muttukrishna,  L.G. Nardo, S.M. Nelson,  H.Y. Ng,  B. Popovic-423 
Todorovic,  J.M.J. Smeenk,  C. Tomás,  P.J.Q. Van der Linden,  I.A. van Rooij, I.K. Vladimirov, and 424 
F.J.M. Broekmans 425 
 426 
 427 
Analyses: S.L. Broer, M. Dólleman J. van Disseldorp, K.A. Broeze, B.C. Opmeer, P. Bossuyt and 428 
M.J.C. Eijkemans 429 
Interpretation of the results and writing of the article: S.L. Broer, M. Dólleman, J. van Disseldorp, 430 
K.A. Broeze, B.C. Opmeer, P. Bossuyt, M.J.C. Eijkemans, B.W. Mol and F.J.M. Broekmans 431 
Revision of the article: all authors.  432 
 433 
Funding 434 
This project was funded by CVZ (Assembly of health insurances in the Netherlands). However, no 435 
funding bodies had any role in study design, data collection and analysis, decision to publish, or 436 
preparation of the manuscript 437 
 438 
Potential conflict of interests 439 
Prof. F.J.M. Broekmans is a member of the external advisory board for Ferring Pharmaceuticals, 440 
Hoofddorp, The Netherlands. He receives no monetary compensation.  441 
All author authors have no potential conflict of interests.  442 
  443 
  444 
Figure 1. Flowchart of included studies 445 
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Figure 2: Study characteristics according to QUADAS  448 
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 458 
 459 
 460 
Characteristics of all included studies evaluated with the QUADAS checklist. Note that QUADAS was set up for 461 
diagnostic studies and these are all prognostic studies.  Therefore, questions regarding reference test could not 462 
be answered. Some questions specific for ovarian reserve testing and fertility studies were added. All studies 463 
were cohort studies, with the majority prospectively set up. All studies analyzed the results per cycle, some 464 
studies analyzed more cycles per couple, in which case only the first cycle was analyzed. 465 
466 
Table 1. Baseline characteristics from pooled data. 467 
 468 
Legend. 469 
Excessive Response definition: > 15 oocytes retrieved. Duration of subfertility: the period from the cessation of 470 
contraceptive methods or start of unprotected intercourse until the first IVF attempt. Excessive responders N = 471 
894 (18.7%). Non excessive responders = 3,892. 472 
AFC, Antral Follicle Count; AMH, Anti-Müllerian Hormone; FSH, Follicle Stimulating Hormone. 473 
474 
Total population Excessive Responders Non-excessive responder P value
Mean (5th–95th percentile) Mean (5th–95th percentile) Mean (5th–95th percentile)
Female age (years) 34.4 (26.0-42.0) 32.5 (25.0-39.9) 34.7 (26.0-42.0) < 0.001
FSH (IU/L) 7.7 (3.8-14.0) 6.4 (3.5-10.1) 8.7 (3.9-16.0) < 0.001
AFC (number) 12.1 (3.0-25.6) 17.1 (6.0-32.0) 11.0 (3.0-22.0) < 0.001
AMH (ng/ml) 2.5 (0.1-7.6) 4.8 (1.3-10.2) 2.0 (0.1-5.7) < 0.001
BMI (kg/m2) 23.6 (18.6-30.1) 23.4 (18.5-29.4) 23.4 (18.6-30.1) 0.943
Duration of subfertility (years) 4.3 (1.3-10.0) 4.3 (1.5-10.0) 4.3 (1.2-10.0) 0.937
Table 2. Univariable and multivariable models of age and ORTs in the prediction of an excessive 475 
response 476 
 477 
 478 
Legend. 479 
Results of random intercept logistic regression model in the prediction of an excessive response. Multivariable 480 
analyses showed that all three ORTs add predictive information to female age alone. P values reflect whether 481 
the variable plays a significant role in the model.  The column “Variance RI” denotes the estimated 482 
variance of the random intercept in the Random intercept logistic model. It’s square root is  the 483 
estimated standard deviation (SD) , and may be interpreted on the logistic scale. A one SD difference 484 
between two studies in the population of studies corresponds to an increase in the Odds on the 485 
outcome (excessive response) of exp(SD). E.g. the Age and AMH model for excessive response  has 486 
variance RI = 0.321, so exp(sqrt(0.321))=1.76, is the relative increase in Odds of excessive response 487 
corresponding to a difference between two studies in intercept of one SD. 488 
OR (Odds Ratio), 95% CI (95% Confidence Interval). 489 
 490 
 491 
 492 
  493 
OR 95% CI P - value Variance-RI OR 95% CI P - value Variance-RI
Univariable models
Age (per year) 0.89 0.85 - 0.93 <0.001 0.748 0.90 0.88 - 0.91 <0.001 0.543
FSH (per IU/L) 0.76 0.70 - 0.84 <0.001 1.23 0.83 0.80 - 0.86 <0.001 0.551
AFC (per N) 1.18 1.15 - 1.22 <0.001 0.715 1.14 1.12 - 1.16 <0.001 0.605
AMH (per 1.0 ng/ml) 1.61 1.48 - 1.76 <0.001 0.878 1.59 1.49 - 1.70 <0.001 0.680
Multivariable models
Age and FSH
Age (per year) 0.91 0.87 - 0.94 <0.001 0.91 0.89 - 0.93 <0.001
FSH (per IU/L) 0.79 0.72 - 0.87 <0.001 0.85 0.82 - 0.88 <0.001
Age and AFC
Age (per year) 0.93 0.89 - 1.98 0.003 0.95 0.92 - 0.98 0.001
AFC (per N) 1.17 1.13 - 1.21 <0.001 1.13 1.11 - 1.15 <0.001
Age and AMH
Age (per year) 0.92 0.88 - 0.97 <0.001 0.92 0.89 - 0.95 <0.001
AMH (per 1.0 ng/ml) 1.57 1.43 - 1.71 <0.001 1.54 1.44 - 1.64 <0.001
Three test study group (N= 1,023) Total study group (N= 4,786)
0.497
0.575
0.599
0.82
0.769
0.596
Table 3.  AUCs of prediction models of age and ovarian reserve tests for the prediction of an 494 
excessive response 495 
 496 
Legend. 497 
The Area Under the Curve (AUC) of the univariable and multivariable models of age or ORTs in the 498 
prediction of an excessive response are shown. In the univariable analysis it is shown that both AMH 499 
and AFC have a high accuracy, while FSH only has a moderate accuracy. In the multivariable models 500 
the added value to the AUC of an ORT on female age is shown, the p value indicates whether this 501 
added value is significant in comparison to the model based on age alone. Adding any of the ORTs 502 
shows a significant rise in the AUC. Moreover, the added value of adding several ORTs to female age 503 
is shown. The model including age, AFC and AMH reached the maximum predictive power. Addition 504 
of FSH to this model did not improve the predictive accuracy (P = 0.725). However, a model with 505 
AMH and AFC alone has a comparable AUC.   506 
 507 
508 
AUC 95% CI  P value N AUC 95% CI  P value N
Univariable analysis
Age 0.61 0.54 - 0.68   NA 1023 0.61 0.58 - 0.64   NA 4650
FSH 0.66 0.60 - 0.73    0.071 1023 0.64 0.61 - 0.67    0.026 4254
AFC 0.79  0.74 - 0.85 < 0.001 1023 0.73 0.69 - 0.77 < 0.001 2524
AMH 0.81 0.76 - 0.87 < 0.001 1023 0.82 0.77 - 0.86 < 0.001 1890
Multivariable analysis
Age & FSH 0.68  0.62 - 0.75 < 0.001 1023 0.67 0.64 - 0.71 < 0.001 4254
Age & AFC 0.81  0.76 - 0.87 < 0.001 1023 0.75 0.71 - 0.79 < 0.001 2524
Age & AMH 0.81 0.76 - 0.87 < 0.001 1023 0.81 0.77 - 0.85 < 0.001 1890
Age & AMH & AFC 0.85 0.80 - 0.90 < 0.001 1023 0.85 0.80 - 0.90 < 0.001 1024
Age & AMH & AFC & FSH 0.85 0.80 - 0.90 < 0.001 1023 0.85 0.80 - 0.90 < 0.001 1023
AMH & AFC 0.85 0.80 - 0.90 < 0.001 1023 0.85 0.80 - 0.90 < 0.001 1024
Three test study group Total study group
Figure 2 ROC curves of age and ORTs in the prediction of an excessive response 509 
 510 
Legend. 511 
The ROC curves of age and age combined with a single or more ORTs are depicted. The ROC curves for ‘Age + 512 
AMH’, ‘Age + AFC’, ‘Age + AMH + AFC’ and ‘Age + AMH + AFC + FSH’ run toward the upper left corner of 513 
the ROC space, indicating a good capacity to discriminate between normal and excessive responders at certain 514 
cut-off levels.NB ROC curves in the three-test study group (N = 1023). AFC, Antral Follicle Count; AMH, Anti-515 
Müllerian Hormone; FSH, Follicle Stimulating Hormone; ORT, Ovarian Reserve Test; ROC, receiver-operating 516 
characteristic. 517 
518 
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Table 4. Results of the ROC regression analysis. 519 
 520 
 521 
Legend. 522 
ROC regression analysis showing the effect of the patient characteristics on the ROC curve of the 523 
ovarian reserve tests in the prediction of an excessive ovarian response. 524 
Bold = significant influence of the patient characteristics on the discriminatory capacity of the ovarian reserve 525 
test in the prediction of an excessive response. AFC = Antral Follicle Count; AMH = Anti-Müllerian Hormone; 526 
FSH = Follicle Stimulating Hormone; Duration= Duration of subfertility. 527 
 528 
 529 
Coefficient 95%  CI P-value 
Age
FSH -0.029  -0.051 - -0.006  0.010
AFC 0.032   0.006 -  0.056  0.010
AMH -0.021  -0.049 -  0.005 0.139 
BMI
FSH 0.026  -0.024 - 0.070 0.267
AFC -0.009  -0.048 - 0.033 0.674
AMH 0.019  -0.024 - 0.056 0.363
Duration
FSH 0.018  -0.044 - 0.078 0.569
AFC 0.047  -0.022 - 0.112 0.177
AMH -0.041  -0.113 - 0.026 0.246
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Figure A-1. Baseline characteristics of the included studies 
A. Number of patients per study 
 
 B. Incidence of an excessive response per study 
17 Popovic 2003a 
18 Popovic 2003b 
19 Vladimirov  
20 La Marca 
21 van der Linden 
22 Eldar-Geva 
23 Jayaprakasan 
24  Smeenk 2007 
25 Copperman 
26 Ebner 
27 van Rooij 
28 Freour 
29 Aflatoonian 
30 Gnoth 
31 Nardo *unpublished 
32 Nardo 2008 
 
Prevalence of Excessive Response per Study
0
10
20
30
40
50
60
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Study Number
Pr
ev
al
en
ce
 o
f e
xc
es
si
ve
 re
sp
on
se
 (%
)
LEGEND: 
1 Kwee 
2 Ng 2000 
3 Ng 2005 
4 Caroppo 
5 Anderson 
6 Klinkert  
7 Nelson 
8 Merce 
9 Bancsi 
10 Tomàs 
11 Greenblatt 
12 Muttukrishna 2004 
13 Muttukrishna 2005 
14 Ashrafi 
15 Erdem 
16 McIlveen 
 
 
C. Patient Characteristics 
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D. Ovarian Reserve Tests 
 
 
Legend: 
 A. The number of patients per study are demonstrated 
B. The prevalence of an excessive response per study is demonstrated 
C. For each individual study the mean, 5th and 95th percentile of the patient characteristics female age, 
    BMI and duration of subfertility are shown.  
D. For each individual study the mean, 5th and 95th percentile of ovarian reserve tests FSH, AFC and 
    AMH are shown.  
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13 Muttukrishna 2005
14 Ashrafi
15 Erdem
16 McIlveen
Table A-1. AUCs of the included studies in the prediction of an excessive response 
Study
AUC N AUC N AUC N
Aflatoonian 0.60 (0.50-0.69) 143 0.96 (0.93-0.99) 143 0.94 (0.90-0.98) 143
Anderson 0.92 (0.99-1.00) 46 0.61(0.67-0.85) 46 NA
Ashrafi 0.59 (0.31-0.87) 50 NA NA
Bancsi 0.61(0.54-0.68) 505 NA NA
Caroppo 0.81(0.72-0.90) 76 NA NA
Copperman 0.65 (0.60-0.69) 570 NA NA
Ebner 0.61 (0.46-0.75) 127 NA 0.82 (0.74-0.90) 135
Eldar-Geva 0.71(0.57-0.85) 52 0.88 (0.75-1.00) 36 0.75 (0.62-0.88) 54
Erdem 0.77 (0.57-0.97) 24 0.85 (0.70-1.00) 24 NA
Freour 0.58 (0.41-0.73) 62 NA 0.70 (0.55-0.86) 64
Gnoth 0.64 (0.51-0.78) 122 NA 0.87 (0.79-0.95) 134
Greenblatt 0.67(0.59-0.74) 261 0.69 (0.61-0.77) 223 NA
Jayaprakasan 0.74(0.57-0.91) 100 0.82 (0.70-0.95) 100 NA
Klinkert 0.42 (0.30-0.55) 212 0.45 (0.33-0.57) 221 NA
Kwee 0.79 (0.70-0.88) 109 0.87 (0.82-0.96) 109 0.84 (0.76-0.92) 105
La Marca NA NA 0.90 (0.76-1.00) 118
McIlveen No >15 71 No >15 71 No >15
Merce NA 0.62 (0.42-0.83) 65 NA
Muttukrishna 1 0.81 (0.59-1.00) 66 NA 0.92 (0.83-1.00) 66
Muttukrishna 2 0.67 (0.52-0.82) 68 0.84 (0.73-0.94) 68 0.73 (0.56-0.91) 68
Nardo 1 0.65 (0.53-0.77) 135 0.71(0.59-0.83) 123 0.74 (0.64-0.83) 135
Nardo 2 0.68 (0.59-0.77) 145 0.71(0.63-0.80) 145 0.79 (0.72-0.87) 145
Nelson 0.64 (0.58-0.71) 338 NA 0.88 (0.82-0.91) 319
Ng 1 0.70 (0.56-0.83) 131 0.80 (0.70-0.90) 131 NA
Ng 2 0.72 (0.56-0.83) 109 0.77 (0.68-0.85) 127 NA
Popovic 1 0.62 (0.54-0.71) 256 0.71(0.63-0.80) 256 NA
Popovic 2 0.62 (0.50-0.73) 143 0.76 (0.67-0.86) 143 NA
Smeenk 1 0.54 (0.40-0.68) 80 0.66 (0.5300.79) 80 0.71 (0.57-0.84) 80
Smeenk 2 NA NA NA
Tomas NA 0.82 (0.72-0.91) 160 NA
Van Rooij 0.68 (0.58-0.79) 215 0.86 (0.79-0.93) 215 0.87 (0.77-0.97) 215
Van der Linden 0.82 (0.72-0.92) 124 NA NA
Vladimirov 2 0.67 (0.48-0.87) 39 0.74 (0.52-0.97) 39 0.80 (0.67-0.93) 39
FSH AFC AMH
Table A-2. Univariable and multivariable models of patient characteristics in the prediction of 
an excessive response 
 
Legend. 
OR = Odds Ratio, 95%CI = 95% Confidence Interval. Duration = duration of subfertility. 
 
 
  
OR 95%  CI P - value OR 95%  CI P - value
Univariable models
Age 0.89 0.85 - 0.93 < 0.001 0.90 0.88 - 0.91 < 0.001
BMI 0.98 0.93 - 1.03    0.405 1.00 0.97 - 1.03    0.954
Duration 0.98 0.90 - 1.06    0.555 0.97 0.92 - 1.01    0.156
Multivariable models
Age and BMI
Age 0.91 0.87 - 0.95 < 0.001 0.9 0.87 - 0.93 < 0.001
BMI 0.99 0.93 - 1.04    0.616 1.00 0.97 - 1.04    0.976
Age and duration
Age 0.90 0.85 - 0.94 < 0.001 0.89 0.86 - 0.91 < 0.001
Duration 1.01 0.93 - 1.10    0.750 1.00 0.95 - 1.05    0.956
Excessive Response Prediction 
Three test study group Total study group
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